{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:31Z","timestamp":1793499991265,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell (CAR-T) treatment for B-cell acute lymphoblastic leukemia (ALL) induces high initial response rates, but most patients relapse. Low disease burden (often defined as &amp;lt;5% blasts in the bone marrow) is associated with better outcomes. CAR HEMATOTOX (HT) is a score using prelymphodepletion hematologic and inflammatory parameters to predict outcomes in lymphoma. Here, we assess its prognostic utility in a large multicenter adult B-cell ALL cohort. Patients who received brexucabtagene autoleucel across 33 centers in North America were included as part of the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) consortium. An independent cohort of 61 patients with ALL treated with an investigational CD19 CAR-T therapy at 1 center was also described. Among 199 ROCCA consortium patients, 43 (22%) patients with HTlow scores had lower rates of delayed neutrophil recovery than those with HThigh scores (26% vs 52%, P = .002) and fewer severe infections (2.5% vs 18.8%, P = .011). They also had higher response rates, overall survival (OS), and event-free survival (EFS), as well as lower nonrelapse mortality and cumulative incidence of relapse. The survival differences remained significant after multivariable adjustment for disease burden and other covariates. In the investigational cohort of 61 patients, patients with HTlow scores had improved OS and EFS, as well as higher peak CAR-T expansion. In summary, CAR HT score is a prognostic factor independent of disease burden in adult ALL. HTlow score is associated with superior outcomes after CD19 CAR-Ts and higher CAR-T expansion in a single-center cohort. These trials were registered at www.clinicaltrials.gov as #NCT01044069 and #NCT01860937.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017526","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:21:34Z","timestamp":1759782094000},"page":"276-288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"first","affiliation":[{"name":"1Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"3Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nemirovsky","sequence":"additional","affiliation":[{"name":"4Biostatistics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[{"name":"4Biostatistics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[{"name":"2Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[{"name":"5Cell Therapy and Cell Engineering Facility, Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Wang","sequence":"additional","affiliation":[{"name":"5Cell Therapy and Cell Engineering Facility, Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"6Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-4434","authenticated-orcid":false,"given":"Nikeshan","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Miller","sequence":"additional","affiliation":[{"name":"8Quantitative Sciences Unit, Biomedical Informatics Research (BMIR) Division, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhang","sequence":"additional","affiliation":[{"name":"8Quantitative Sciences Unit, Biomedical Informatics Research (BMIR) Division, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[{"name":"9Division of Hematology and Medical Oncology, Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Al Darobi","sequence":"additional","affiliation":[{"name":"10Section of Hematology, Department of Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Muhsen","sequence":"additional","affiliation":[{"name":"11Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-462X","authenticated-orcid":false,"given":"Joshua","family":"Sasine","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[{"name":"14Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"15Blood and Marrow Transplantation and Cell Therapy Program, Department of Medicine, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-215X","authenticated-orcid":false,"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[{"name":"16Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Kopmar","sequence":"additional","affiliation":[{"name":"17Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"},{"name":"18Department of Medicine, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Tsai","sequence":"additional","affiliation":[{"name":"19Division of Hematology\/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[{"name":"20Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"21Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-781X","authenticated-orcid":false,"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"21Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem M.","family":"Solh","sequence":"additional","affiliation":[{"name":"22Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Tan","sequence":"additional","affiliation":[{"name":"23Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-5697","authenticated-orcid":false,"given":"Evandro","family":"Bezerra","sequence":"additional","affiliation":[{"name":"24Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Battiwalla","sequence":"additional","affiliation":[{"name":"25Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"26Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, Division of Hematology\/Oncology, Department of Internal Medicine, HCA Healthcare, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mathews","sequence":"additional","affiliation":[{"name":"27Sarah Cannon Transplant and Cellular Therapy Program at Texas Oncology, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"28Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mountjoy","sequence":"additional","affiliation":[{"name":"29Sarah Cannon Transplant and Cellular Therapy Program at Colorado Blood Cancer Institute, Division of Hematology and Oncology, Department of Internal Medicine, HCA Healthcare, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus T.","family":"Hoeg","sequence":"additional","affiliation":[{"name":"30Division of Cellular Therapy, Bone Marrow Transplantation and Malignant Hematology, Department of Internal Medicine, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-1755","authenticated-orcid":false,"given":"Kaitlyn C.","family":"Dykes","sequence":"additional","affiliation":[{"name":"31Division of Hematology and Medical Oncology, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"32Division of Hematology and Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu V.","family":"Kumaran","sequence":"additional","affiliation":[{"name":"33Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, University of Arkansas Medical Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"34Division of Hematology, Department of Medicine, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Tracy","sequence":"additional","affiliation":[{"name":"35Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-5790","authenticated-orcid":false,"given":"Jozal","family":"Moore","sequence":"additional","affiliation":[{"name":"36Division of Hematology and Oncology, Department of Internal Medicine, Wilmot Cancer Institute of University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-7727","authenticated-orcid":false,"given":"Silvina","family":"Odstrcil Bobillo","sequence":"additional","affiliation":[{"name":"37Division of Hematology and Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[{"name":"38Division of Hematology and Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-0623","authenticated-orcid":false,"given":"Matthew","family":"Connor","sequence":"additional","affiliation":[{"name":"38Division of Hematology and Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9598-6467","authenticated-orcid":false,"given":"Abdullah","family":"Ladha","sequence":"additional","affiliation":[{"name":"39Department of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"40Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5935-8279","authenticated-orcid":false,"given":"Katherine","family":"Sutherland","sequence":"additional","affiliation":[{"name":"41Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-5152","authenticated-orcid":false,"given":"Gregory W.","family":"Roloff","sequence":"additional","affiliation":[{"name":"42Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"41Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"1Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"5","key":"2026011311213212200_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"2026011311213212200_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"2026011311213212200_bib3","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2023","journal-title":"New Engl J Med"},{"issue":"9","key":"2026011311213212200_bib4","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026011311213212200_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026011311213212200_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026011311213212200_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"JCO"},{"issue":"14","key":"2026011311213212200_bib8","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR-T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2026011311213212200_bib9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"JCO"},{"issue":"5","key":"2026011311213212200_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR-therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"2026011311213212200_bib11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR-T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026011311213212200_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR-T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026011311213212200_bib13","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2026011311213212200_bib14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-hematotox (ALL-HT): predicting post CAR-T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"issue":"26","key":"2026011311213212200_bib15","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR-T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2026011311213212200_bib16","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","article-title":"Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"35","author":"Winick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026011311213212200_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026011311213212200_bib18","first-page":"540.e1","article-title":"Defining and grading infections in clinical trials involving hematopoietic cell transplantation: a report from the BMT CTN Infectious Disease Technical Committee","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"2026011311213212200_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2026011311213212200_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2026011311213212200_bib23","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR-T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"2026011311213212200_bib24","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/bloodadvances.2024013146","article-title":"CAR-T-cell expansion: harmful or helpful?","volume":"8","author":"Lionel","year":"2024","journal-title":"Blood Adv"},{"issue":"22","key":"2026011311213212200_bib25","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR-T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026011311213212200_bib26","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1002\/ajh.26551","article-title":"Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias","volume":"97","author":"Tabbara","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026011311213212200_bib27","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2023-186015","article-title":"Targeting normal myelopoiesis negatively affects CAR-T cell activity","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011311213212200_bib28","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2024-208028","article-title":"Risk factors associated with sub-optimal outcomes following obecabtagene autoleucel (obe-cel) for relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL): what we have learned from the FELIX Trial","volume":"144","author":"Roddie","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/276\/2497345\/blooda_adv-2025-017526-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/276\/2497345\/blooda_adv-2025-017526-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:21:41Z","timestamp":1768321301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/276\/547590\/CAR-HEMATOTOX-independently-predicts-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017526","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2026,1,13]]}}}